Ketanserin versus Placebo in Carcinoid Syndrome: A Clinical Controlled Trial

Gustafsen J, Lendorf A, Raskov H, Boesby S. Ketanserin versus placebo in carcinoid syndrome. A clinical controlled trial. Scand J Gastroenterol 1986, 21, 816-818 Seven patients, four women and three men, with a median age of 64 years (range, 53-74 years) were randomized to treatment with either keta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scandinavian journal of gastroenterology 1986-01, Vol.21 (7), p.816-818
Hauptverfasser: Gustafsen, J., Lendorf, A., Raskov, H., Boesby, S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Gustafsen J, Lendorf A, Raskov H, Boesby S. Ketanserin versus placebo in carcinoid syndrome. A clinical controlled trial. Scand J Gastroenterol 1986, 21, 816-818 Seven patients, four women and three men, with a median age of 64 years (range, 53-74 years) were randomized to treatment with either ketanserin, 40-160 mg daily, or placebo. The study included 13 treatment periods with ketanserin and 13 with placebo. All patients had typical symptoms, with flushing as their main complaint. The diagnosis had been verified histologically. All had elevated excretion of 5-hydroxy-3-indoleacetic acid in urine. During the trial ketanserin reduced the number of flushing attacks in five patients (p < 0.05). Diarrhoea was reduced in two patients. No side effects were observed. Ketanserin seems valuable for the symptomatic relief in the carcinoid syndrome.
ISSN:0036-5521
1502-7708
DOI:10.3109/00365528609011123